Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 25% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-06-05. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticevidencetherapyactivesyndrome
  Phrases that lowered it: bloodsubject whosafety ofkidneypressure
• Sponsor's past termination rate: 29.1% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 163 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 282 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 20% (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 30 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion NCT03494816 · started 2017 · scored riskier than 97% of active trials completed
• NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma NCT01649180 · started 2012 · scored riskier than 99% of active trials terminated
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer NCT04337970 · started 2020 · scored riskier than 60% of active trials completed
• A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy NCT01693822 · started 2012 · scored riskier than 98% of active trials completed
• Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer NCT02579811 · started 2015 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.